Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients with Heart Failure | JACC

In this episode, Dr. Valentin Fuster discusses a study on sodium zirconium cyclosilicate (SZC) for managing hyperkalemia in heart failure patients on mineralocorticoid receptor antagonists (MRAs) like spironolactone. While SZC effectively reduced hyperkalemia and allowed higher spironolactone doses, concerns over worsening heart failure events highlight the complex balance between treatment benefits and risks.

Episode metadata supplied by the publisher feed · Published Mar 10, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients with Heart Failure | JACC

0:00 8:08

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of JACC This Week?

This episode is 8 minutes long.

When was this JACC This Week episode published?

This episode was published on March 10, 2025.

Can I download this JACC This Week episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!